| Primary information |
|---|
| sequence ID | Seq_7509 |
| Peptide sequence | SPSGEVSHPR |
| CancerPDF_ID | CancerPDF_ID1660, CancerPDF_ID9650, CancerPDF_ID12240, |
| PMID | 21136997,21533267,26992070 |
| Protein Name | Alpha-2-HS-glycoprotein,Alpha-2-HS-glycoprotein,Alpha-2-HS-glycoprotein |
| UniprotKB Entry Name | FETUA_HUMAN,FETUA_HUMAN,FETUA_HUMAN |
| Fluid | Serum,Serum,Serum |
| M/Z | 1051.50467,526.76,1051.5047 |
| Charge | 1,2,NA |
| Mass (in Da) | NA,NA,1052.514208 |
| fdr | NA,NA,NA |
| Profiling Technique | LC-MS,LC-MS,LC-MS |
| Peptide Identification technique | LC-MS-MS/MS,LC/MS/MS,LC-MS/MS |
| Quantification Technique | LC-ESI-MS,Multiple Reaction Monitoring,NA |
| Labelled/Label Free | Label Free,Label Free,Label Free |
| FDR | NA,1.49,FDR 1 % |
| CancerPDF_ID | CancerPDF_ID1660, CancerPDF_ID9650, CancerPDF_ID12240, |
| p-Value | NA,NA,NA |
| Software | MASCOT(v. 2.2.01),MASCOT,SEQUEST and Maxquant |
| Length | 10,10,10 |
| Cancer Type | Colorectal cancer,Lung adenocarcinoma,Melanoma |
| Database | SwissProt Database,Swissprot Database (57.4),SwissProt Database |
| Modification | NA,NA,NA |
| Number of Patients | 30 patients and 30 healthy controls,62 lung adenocarcinoma and 30 healthy control,8 cancer samples and 4 healthy samples |
| Regulation | NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." |
| Validation | Leave One out Cross validation,MRM-based validation of 19 candidates,na |
| Sensitivity | NA,NA,NA |
| Specificity | NA,NA,NA |
| Accuracy | NA,NA,NA |
| Peptide Atlas | PeptideAtlas |
| IEDB | |